EP1425011A4 - Enhancement of learning and memory and treatment of amnesia - Google Patents

Enhancement of learning and memory and treatment of amnesia

Info

Publication number
EP1425011A4
EP1425011A4 EP02763634A EP02763634A EP1425011A4 EP 1425011 A4 EP1425011 A4 EP 1425011A4 EP 02763634 A EP02763634 A EP 02763634A EP 02763634 A EP02763634 A EP 02763634A EP 1425011 A4 EP1425011 A4 EP 1425011A4
Authority
EP
European Patent Office
Prior art keywords
sub
memory
amnesia
learning
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02763634A
Other languages
German (de)
French (fr)
Other versions
EP1425011A2 (en
EP1425011B1 (en
Inventor
Wen-Mei Fu
Keng-Chen Liang
Wei-Lin Chien
Sheng-Chu Kuo
Fang-Yuan Lee
Che-Ming Teng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlsbad Technology Inc
Original Assignee
Carlsbad Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsbad Technology Inc filed Critical Carlsbad Technology Inc
Publication of EP1425011A2 publication Critical patent/EP1425011A2/en
Publication of EP1425011A4 publication Critical patent/EP1425011A4/en
Application granted granted Critical
Publication of EP1425011B1 publication Critical patent/EP1425011B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method for enhancing learning and memory or treating amnesia. The method includes administrating to a subject in need thereof a compound of the formula (I): A is H, R, or each of Ar<SUB>1</SUB>, Ar<SUB>2</SUB>, and Ar<SUB>3</SUB>, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, R<SUB>5</SUB>, and R<SUB>6</SUB>, independently, is H, nitro, halogen, R, OH, OR, C(O)OH, C(O)OR, C(O)SH, C(O)SR, C(O)NH<SUB>2</SUB>, C(O)NHR, C(O)NRR', ROH, ROR', RSH, RSR', ROC(O)R'OH, NHR, NRR', RNHR', or RNR'R''; or R<SUB>1 </SUB>and R<SUB>2 </SUB>together, R<SUB>3 </SUB>and R<SUB>4 </SUB>together, or R<SUB>5 </SUB>and R<SUB>6 </SUB>together are ORO; wherein each of R, R', and R'', independently is C<SUB>1</SUB>~C<SUB>6 </SUB>alkyl; and n is 1, 2, or 3. The compound is in an effective amount for enhancing learning and memory or treating amnesia.
EP02763634A 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia Expired - Lifetime EP1425011B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32238901P 2001-09-14 2001-09-14
US322389P 2001-09-14
US242826 2002-09-13
US10/242,826 US7049334B2 (en) 2001-09-14 2002-09-13 Enhancement of learning and memory and treatment of amnesia
PCT/US2002/029294 WO2003024397A2 (en) 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia

Publications (3)

Publication Number Publication Date
EP1425011A2 EP1425011A2 (en) 2004-06-09
EP1425011A4 true EP1425011A4 (en) 2007-09-19
EP1425011B1 EP1425011B1 (en) 2009-11-04

Family

ID=26935379

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02763634A Expired - Lifetime EP1425011B1 (en) 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia

Country Status (10)

Country Link
US (1) US7049334B2 (en)
EP (1) EP1425011B1 (en)
JP (1) JP2005502722A (en)
KR (1) KR100889515B1 (en)
AT (1) ATE447405T1 (en)
AU (1) AU2002327635B2 (en)
CA (1) CA2460005C (en)
DE (1) DE60234263D1 (en)
NZ (1) NZ532022A (en)
WO (1) WO2003024397A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc Compounds, compositions and methods
JP2005089457A (en) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd Pharmaceutical composition for promoting bone growth or inhibiting bone resorption
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP2046122A4 (en) * 2006-07-24 2009-12-23 Univ Maryland Heme oxygenase inhibitors and methods of therapeutic use
CA2671524A1 (en) * 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (en) * 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
WO2001016359A2 (en) * 1999-08-31 2001-03-08 University College London Screen for axon viability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240947A (en) * 1992-11-30 1993-08-31 National Science Council 2,3,4,5-substituted furo[2,3-c]pyrazole derivatives
JP2928079B2 (en) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
DE19744026A1 (en) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazole derivatives, their preparation and their use in medicinal products
WO2001054680A2 (en) * 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
AR031176A1 (en) * 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (en) * 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
WO2001016359A2 (en) * 1999-08-31 2001-03-08 University College London Screen for axon viability

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOULTON C L ET AL: "Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase", NEUROSCIENCE, vol. 69, no. 3, 1995, pages 699 - 703, XP002445183, ISSN: 0306-4522 *
BREDT, DAVID S.: "Nitric oxide signaling in brain: potentiating the gain with YC-1", MOLECULAR PHARMACOLOGY , 63(6), 1206-1208 CODEN: MOPMA3; ISSN: 0026-895X, 2003, XP002445185 *
CHIEN, WEI-LIN ET AL: "Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1- benzylindazole", MOLECULAR PHARMACOLOGY , 63(6), 1322-1328 CODEN: MOPMA3; ISSN: 0026-895X, 2003, XP002445186 *
MONFORT PILAR ET AL: "Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE 1 DEC 2002, vol. 22, no. 23, 1 December 2002 (2002-12-01), pages 10116 - 10122, XP002445184, ISSN: 1529-2401 *

Also Published As

Publication number Publication date
US7049334B2 (en) 2006-05-23
KR100889515B1 (en) 2009-03-19
AU2002327635B2 (en) 2007-12-13
CA2460005A1 (en) 2003-03-27
CA2460005C (en) 2008-12-02
NZ532022A (en) 2005-12-23
JP2005502722A (en) 2005-01-27
US20030105149A1 (en) 2003-06-05
DE60234263D1 (en) 2009-12-17
WO2003024397A2 (en) 2003-03-27
EP1425011A2 (en) 2004-06-09
EP1425011B1 (en) 2009-11-04
KR20040049307A (en) 2004-06-11
WO2003024397A3 (en) 2003-11-06
ATE447405T1 (en) 2009-11-15

Similar Documents

Publication Publication Date Title
CY1111951T1 (en) PAINYL-CARBOXAMID COMPOUNDS USEFUL FOR PANTS
BR0109165A (en) Cholemic polyps treatment method
NO20003233D0 (en) 4-hydroquinquinoline-3-carboxamides and hydrazines as antivirals
EA200100412A1 (en) SUBSTITUTED 3-CYANOHINOLINES AS PROTEINTHYROSINKINASE INHIBITORS
EA200500453A1 (en) IMIDAZOPIRIDINES AND METHODS FOR THEIR RECEPTION AND APPLICATION
HK1079522A1 (en) Thienyl compounds
BRPI0415449A (en) Synergistic fungicidal active compound combinations
HRP20050517B1 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
HK1085675A1 (en) Anticancer compounds
EP1425011A4 (en) Enhancement of learning and memory and treatment of amnesia
DK1000034T3 (en) Substituted 6-alkylphenanthridines
TW200600084A (en) Anti-coronavirus compounds
TW200510329A (en) Treatment of neurodegenerative diseases
TR199900153T2 (en) Substituted bisindolylmaleimides to prevent cell proliferation.
TW200724137A (en) Cancer treatment
TW200510330A (en) Enhancement of bone growth and inhibition of bone resorption
NO20030500D0 (en) Dihydroporphyrin derivatives and their use
DK1651596T3 (en) Novel derivatives of 4,4&#39;-dithiobis (3-aminobutane-1-sulfonates) and compositions comprising the same
JP2005502722A5 (en)
MXPA05003909A (en) Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer.
TH31815B (en) A fungicide containing 3- Fenilpiresol
EA200600614A1 (en) FUNGICIDAL MIXTURES FOR STRUGGLE AGAINST RICE PATHOGENS
TH31815A (en) A fungicide containing 3- Fenilpiresol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040322

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TENG, CHE-MING

Inventor name: CHIEN, WEI-LIN

Inventor name: LEE, FANG-YUAN

Inventor name: LIANG, KENG-CHEN

Inventor name: KUO, SHENG-CHU

Inventor name: FU, WEN-MEI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/415 20060101AFI20040325BHEP

Ipc: A61P 25/28 20060101ALI20070802BHEP

Ipc: A61K 31/4162 20060101ALI20070802BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070821

17Q First examination report despatched

Effective date: 20080306

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60234263

Country of ref document: DE

Date of ref document: 20091217

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100215

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100304

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100204

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100916

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100916

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20210916

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210831

Year of fee payment: 20

Ref country code: DE

Payment date: 20210831

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60234263

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220915